Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Werba Rubin Papier Wealth Management

Werba Rubin Papier Wealth Management cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 43.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,916 shares of the biopharmaceutical company's stock after selling 6,179 shares during the quarter. Werba Rubin Papier Wealth Management's holdings in Gilead Sciences were worth $731,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Avior Wealth Management LLC increased its position in Gilead Sciences by 1.2% during the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock worth $782,000 after purchasing an additional 108 shares during the last quarter. Southland Equity Partners LLC increased its position in shares of Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock worth $289,000 after acquiring an additional 110 shares in the last quarter. Concord Asset Management LLC VA increased its position in shares of Gilead Sciences by 3.8% in the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company's stock worth $256,000 after acquiring an additional 111 shares in the last quarter. Berkshire Bank increased its position in shares of Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 111 shares in the last quarter. Finally, TFB Advisors LLC increased its position in shares of Gilead Sciences by 1.2% in the third quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company's stock worth $788,000 after acquiring an additional 116 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded down $0.08 during trading hours on Friday, reaching $109.95. The company's stock had a trading volume of 9,729,048 shares, compared to its average volume of 7,379,648. The company's 50 day simple moving average is $95.41 and its 200 day simple moving average is $88.63. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $111.03. The stock has a market cap of $137.03 billion, a P/E ratio of 297.16, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a $0.79 dividend. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.87%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is presently 832.43%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total value of $260,225.00. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $17,597,559.49. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 713,000 shares of company stock worth $67,945,181. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. UBS Group increased their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. Daiwa America raised shares of Gilead Sciences to a "hold" rating in a research report on Monday, November 18th. Wolfe Research assumed coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They issued an "outperform" rating and a $110.00 price objective for the company. Morgan Stanley increased their price objective on shares of Gilead Sciences from $113.00 to $123.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.